Indaptus Therapeutics, Inc.INDPNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +13.21% | +11.36% | +10.82% | -93.27% | -89.52% |
| Weighted Average Shares Diluted Growth | +13.21% | +11.36% | +10.82% | -93.27% | -89.52% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -53.69% | -50.83% | -50.57% | -15.79% | -16.99% |
| Book Value per Share Growth | -65.42% | -70.67% | -73.01% | +0.00% | +631.81% |
| Debt Growth | -44.97% | -51.92% | -61.14% | +4897.54% | -91.96% |
| R&D Expense Growth | -34.16% | +21.89% | +76.66% | +26.44% | +3.53% |
| SG&A Expenses Growth | -17.10% | -21.14% | -25.10% | -4.40% | -32.53% |